PubRank

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Clinical Trial ID NCT00486668

PubWeight™ 17.46‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00486668

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011 4.12
2 Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013 2.59
3 MYC in breast tumor progression. Expert Rev Anticancer Ther 2008 1.49
4 Treatment of HER2-positive breast cancer. Breast 2013 1.09
5 Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol 2011 1.03
6 The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol 2009 0.98
7 Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 2014 0.96
8 Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics 2011 0.83
9 The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem 2014 0.80
10 Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol 2010 0.79
11 Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012 0.79
12 Breast cancer: HER2--a good addiction. Nat Rev Clin Oncol 2012 0.78
13 Are we HER-ting for innovation in neoadjuvant breast cancer trial design? Breast Cancer Res 2009 0.77
14 Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol 2016 0.75
Next 100